# Ultrasound Attenuation Coefficient as a Biomarker of Hepatic Steatosis: State of the Art and Software Evaluation

## TL;DR

This paper reviews how ultrasound attenuation coefficient measurements can be used as a reliable biomarker for liver steatosis, but highlights the need for standardization across different ultrasound systems.

## Contribution

The paper evaluates current AC-based technologies and emphasizes the need for harmonization to improve cross-platform comparability.

## Key findings

- AC values strongly correlate with MRI-PDFF and histopathological grading of liver steatosis.
- Commercial AC software implementations differ in design and processing, affecting diagnostic thresholds.
- Standardized protocols and cross-calibration are needed to ensure reliable clinical use of AC measurements.

## Abstract

Background/Objectives: The attenuation coefficient (AC) is a quantitative ultrasound parameter that describes the frequency-dependent reduction of acoustic energy as ultrasound waves propagate through biological tissues. Recently, AC has gained increasing relevance in abdominal ultrasound as an objective and reproducible biomarker for tissue characterization, particularly in the assessment of diffuse parenchymal diseases. Unlike conventional qualitative B-mode imaging, AC provides standardized numerical measurements that improve interobserver reproducibility and facilitate longitudinal monitoring. Methods: This review provides a comprehensive and critical overview of the current clinical applications of AC measurements in abdominal ultrasound, mainly focusing on liver steatosis quantification. Emphasis is placed on the comparative evaluation of commercially available AC-based technologies, highlighting their methodological differences, validation evidence, and diagnostic performance to support future efforts toward harmonization and standardization across ultrasound platforms. Results: Several studies have demonstrated a strong correlation between AC values and established reference standards, including magnetic resonance imaging–proton density fat fraction (MRI-PDFF) and histopathological grading, supporting its role in the noninvasive evaluation of liver steatosis. The growing clinical adoption of AC has been accompanied by the development of multiple vendor-specific software implementations integrated into modern ultrasound systems. Although these platforms share a common physical basis, they differ substantially in algorithmic design, signal processing strategies and region-of-interest selection. These differences may influence absolute AC values and diagnostic cutoff thresholds, therefore limiting direct comparability across systems. Another factor that further contributes to the heterogeneity of reported cutoff values is the variability in validation approaches, with some technologies validated against liver biopsy and others against MRI-PDFF. Conclusions: AC is a promising quantitative ultrasound biomarker for noninvasive liver steatosis assessment, showing strong correlation with histology and MRI-PDFF. However, inter-vendor variability currently limits cross-platform comparability. Standardized acquisition protocols, unified quality-control criteria, phantom-based cross-calibration, and consistent vendor-specific reporting are essential to ensure reliable longitudinal monitoring and broader clinical implementation.